Artiva Biotherapeutics (ARTV) EBIT Margin (2023 - 2024)
Artiva Biotherapeutics' EBIT Margin was -26805.58% in FY2024, down 26714.00 percentage points from -91.58% in FY2023.
Powered by 
Analysis
Artiva Biotherapeutics (ARTV) EBIT Margin (2023 - 2024) Analysis & Trends
- Per Business Quant data, EBIT Margin in earlier years was -91.58% in FY2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 34.46% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 24.35% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 36.01% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 30.74% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 29.12% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 35.79% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 41.71% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 32.98% |
| 10 | Artiva Biotherapeutics | 200.70 Mn | -118.40 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | -5,773.71% |
| Dec 31, 2023 | -509.36% |
| Sep 30, 2023 | 40.56% |
| Jun 30, 2023 | -338.12% |
API Access
Artiva Biotherapeutics EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=ARTV&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "ARTV", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=ARTV&period=max&api_key=YOUR_API_KEY");
const data = await res.json();